Details

Autor(en) / Beteiligte

• Ikramuddin, Sayeed
• Korner, Judith
• Lee, Wei-Jei
• Bantle, John P
• Thomas, Avis J
• Connett, John E
• Leslie, Daniel B
• Inabnet, 3rd, William B
• Wang, Qi
• Jeffery, Robert W
• Chong, Keong
• Chuang, Lee-Ming
• Jensen, Michael D
• Vella, Adrian
• Ahmed, Leaque
• Belani, Kumar
• Olofson, Amy E
• Bainbridge, Heather A
• Billington, Charles J

Titel

Durability of Addition of Roux-en-Y Gastric Bypass to Lifestyle Intervention and Medical Management in Achieving Primary Treatment Goals for Uncontrolled Type 2 Diabetes in Mild to Moderate Obesity: A Randomized Control Trial

Ist Teil von

• Diabetes care, 2016-09, Vol.39 (9), p.1510-1518

Ort / Verlag

United States: American Diabetes Association

Erscheinungsjahr

2016

Quelle

MEDLINE

Beschreibungen/Notizen

• We compared 3-year achievement of an American Diabetes Association composite treatment goal (HbA1c <7.0%, LDL cholesterol <100 mg/dL, and systolic blood pressure <130 mmHg) after 2 years of intensive lifestyle-medical management intervention, with and without Roux-en-Y gastric bypass, with one additional year of usual care. A total of 120 adult participants, with BMI 30.0-39.9 kg/m(2) and HbA1c ≥8.0%, were randomized 1:1 to two treatment arms at three clinical sites in the U.S. and one in Taiwan. All patients received the lifestyle-medical management intervention for 24 months; half were randomized to also receive gastric bypass. At 36 months, the triple end point goal was met in 9% of lifestyle-medical management patients and 28% of gastric bypass patients (P = 0.01): 10% and 19% lower than at 12 months. Mean (SD) HbA1c values at 3 years were 8.6% (3.5) and 6.7% (2.0) (P < 0.001). No lifestyle-medical management patient had remission of diabetes at 36 months, whereas 17% of gastric bypass patients had full remission and 19% had partial remission. Lifestyle-medical management patients used more medications than gastric bypass patients: mean (SD) 3.8 (3.3) vs. 1.8 (2.4). Percent weight loss was mean (SD) 6.3% (16.1) in lifestyle-medical management vs. 21.0% (14.5) in gastric bypass (P < 0.001). Over 3 years, 24 serious or clinically significant adverse events were observed in lifestyle-medical management vs. 51 with gastric bypass. Gastric bypass is more effective than lifestyle-medical management intervention in achieving diabetes treatment goals, mainly by improved glycemic control. However, the effect of surgery diminishes with time and is associated with more adverse events.